-
公开(公告)号：US5948749A
公开(公告)日：1999-09-07
申请号：US922775
申请日：1997-09-03
IPC分类号： A61K9/14 , A61K9/00 , A61K9/18 , A61K38/00 , A61K38/11 , A61K38/21 , A61K38/22 , A61K38/23 , A61K38/24 , A61K38/26 , A61K38/27 , A61K38/28 , A61K38/46 , A61K47/32 , A61P43/00
CPC分类号： A61K9/0043 , A61K38/28
摘要： A pharmaceutical preparation for intranasal administration having a better absorption rate and less irritant effects is provided. The pharmaceutical preparation comprises a mixture of a powder of an adsorbent resin and a biologically active peptide having a drug effect under the condition that they are dry prior to or after the mixing.
摘要翻译： 提供了具有更好吸收速率和较少刺激性作用的鼻内给药用药物。 药物制剂包含吸附树脂粉末和具有药物作用的生物活性肽的混合物，它们在混合之前或之后是干燥的。
-
公开(公告)号：US5723121A
公开(公告)日：1998-03-03
申请号：US812920
申请日：1997-03-10
IPC分类号： A61K38/21 , A61K38/00 , A61P31/12 , A61P35/00 , C07K1/113 , C07K14/52 , C07K14/555 , C07K14/56 , C07K17/10
摘要： Sugar-modified interferon, modified with at least one galactose residue, which is a binding reaction product between lactose lactone and interferon is disclosed. The sugar-modified interferon, which can be obtained through simple chemical manipulation on IFN, has improved accumulating properties in the liver and enhanced physiological activities as compared with unmodified IFN.
摘要翻译： 公开了用至少一种半乳糖残基修饰的糖修饰的干扰素，其是乳糖内酯和干扰素之间的结合反应产物。 通过对IFN进行简单的化学操作可以获得糖修饰的干扰素，与未修饰的IFN相比，改善了肝脏的累积性能和增强的生理活性。
-
3.发明申请Composition containing retinoic acid nanoparticles coated with inorganic salt of polyvalent metal 审中-公开包含用多价金属的无机盐涂覆的视黄酸纳米粒子的组合物公开(公告)号：US20070258926A1
公开(公告)日：2007-11-08
申请号：US10595413
申请日：2003-10-15
IPC分类号： A61K8/04
CPC分类号： A61K8/0241 , A61K8/0291 , A61K8/671 , A61K9/501 , A61K9/5115 , A61K2800/413 , A61K2800/621 , A61Q19/00 , A61Q19/08 , B82Y5/00
摘要： A composition contains nanoparticles of retinoic acid as an active ingredient. The nanoparticles have reduced irritancy of retinoic acid and are suitable for subcutaneous or intravenous administration, as well as for use in sustained-release preparation. The high skin permeability of the nanoparticles makes the composition suitable for use in pharmaceutical or non-pharmaceutical external preparations or cosmetics intended for skin application. The retinoic acid nanoparticles of the present invention are coated with an inorganic salt of polyvalent metal and can be dissolved in water to make a stable clear solution that can be formulated into injectable preparations for subcutaneous and intravenous administration. The polyvalent metal inorganic salt coating helps reduce the irritancy of retinoic acid, so that the nanoparticles do not cause inflammation or tumor formation at the site of application. The inorganic salt of polyvalent metal may be calcium carbonate, zinc carbonate or calcium phosphate.
摘要翻译： 组合物含有视黄酸的纳米颗粒作为活性成分。 纳米颗粒具有降低视黄酸的刺激性，适用于皮下或静脉内施用，以及用于持续释放制剂。 纳米颗粒的高皮肤渗透性使得该组合物适用于用于皮肤应用的药物或非药物外用制剂或化妆品。 本发明的视黄酸纳米粒子涂覆有多价金属的无机盐，可以溶解在水中，形成稳定的透明溶液，将其配制成用于皮下和静脉内给药的可注射制剂。 多价金属无机盐涂层有助于降低视黄酸的刺激性，使得纳米颗粒在施用部位不引起炎症或肿瘤形成。 多价金属的无机盐可以是碳酸钙，碳酸锌或磷酸钙。
-
公开(公告)号：US5504068A
公开(公告)日：1996-04-02
申请号：US975548
申请日：1993-02-23
申请人： Katsuo Komiya , Rie Igarashi , Mitsuko Takenaga , Akira Yanagawa , Yutaka Mizushima , Tateo Nishimura , Toshitaka Kudo , Kunio Ando
发明人： Katsuo Komiya , Rie Igarashi , Mitsuko Takenaga , Akira Yanagawa , Yutaka Mizushima , Tateo Nishimura , Toshitaka Kudo , Kunio Ando
IPC分类号： A61K38/00 , A61K9/00 , A61K38/13 , A61K47/00 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/18 , A61K47/44 , A61P17/00 , A61P37/06 , C08B37/16
CPC分类号： A61K9/0014 , A61K38/13 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/18 , A61K47/44 , Y10S514/885
摘要： A topical preparation containing cyclosporin as an active ingredient, is disclosed that contains (a) cyclosporin; (b) an organic solvent for dissolving the cyclosporin; (c) an ester of a fatty acid with a monovalent alcohol having a total number of carbon atoms of 8 or more and/or an alkanol amine, each being in liquid state at 25.degree.C; (d) an oily substance in solid state at 25.degree.C; and (e) a surfactant. The cyclosporin is present in a concentration ranging from appoximately 0.1% to 10% by weight and the ester and/or alkanol amine are/is present in a concentration ranging from approximately 1% to 15% by weight. The topical preparations are active against atopic dermatitis, psoriasis and allergic contact dermatitis.
摘要翻译： PCT No.PCT / JP92 / 00798 Sec。 371日期：1993年2月23日 102（e）日期1993年2月23日PCT提交1992年6月22日PCT公布。 出版物WO93 / 日本1993年1月7日。公开了含有环孢菌素作为活性成分的局部制剂，其含有（a）环孢菌素; （b）溶解环孢菌素的有机溶剂; （c）脂肪酸与总碳原子数为8以上的一价醇和/或链烷醇胺的酯在25℃处于液态; （d）25℃固态的油状物; 和（e）表面活性剂。 环孢菌素以约0.1重量％至10重量％的浓度存在，酯和/或烷醇胺以约1重量％至15重量％的浓度存在。 局部制剂对抗特应性皮炎，牛皮癣和过敏性接触性皮炎是有活性的。
-
5.发明申请Method of controlling paticle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method 审中-公开通过控制方法获得的用多价金属无机盐和纳米粒子涂覆的视黄酸纳米颗粒的粒度控制方法公开(公告)号：US20070014863A1
公开(公告)日：2007-01-18
申请号：US10595412
申请日：2003-10-15
IPC分类号： A61K9/14 , A61K31/203
CPC分类号： A61K9/5115 , A61K9/1075 , A61K9/5089 , A61K9/5192 , A61K31/203 , A61K47/02
摘要： Nanoparticles containing retinoic acid have reduced irritancy of retinoic acid and are suitable for subcutaneous or intravenous administration, as well as for use in sustained-release preparation. The high skin permeability of the nanoparticles makes them suitable for use in pharmaceutical or non-pharmaceutical external preparations or cosmetics intended for skin application. The present invention provides a method for adjusting the particle size of such nanoparticles and nanoparticles produced by such a method. Specifically, the method involves dispersing retinoic acid dissolved in a lower alcohol in an aqueous alkali solution; adding a nonionic surfactant to the dispersion to form a mixed micelle; adding to the micelle a halide or acetate of divalent metal along with a carbonate or phosphate of alkali metal so that the molar ratio of the former to the latter is 1:0 to 1:1.0, thereby depositing a coating of inorganic salt of polyvalent metal on the surface of the micelle; and adjusting the average particle size of the resulting nanoparticles to 5 to 300 nm. The inorganic salt of polyvalent metal may be calcium carbonate, zinc carbonate, or calcium phosphate.
摘要翻译： 含视黄酸的纳米粒子具有降低视黄酸的刺激性，适用于皮下或静脉内给药以及用于持续释放制剂。 纳米颗粒的高皮肤渗透性使得它们适用于用于皮肤应用的药物或非药物外用制剂或化妆品。 本发明提供了一种调节由这种方法生产的纳米颗粒和纳米粒子的粒径的方法。 具体地说，该方法包括将溶解在低级醇中的视黄酸分散在碱性水溶液中; 向分散体中加入非离子表面活性剂以形成混合胶束; 向胶束中加入二价金属的卤化物或乙酸酯以及碱金属的碳酸盐或磷酸盐，使得前者与后者的摩尔比为1:0至1:1.0，由此沉积多价金属的无机盐的涂层 在胶束的表面上; 并将所得纳米粒子的平均粒径调整为5〜300nm。 多价金属的无机盐可以是碳酸钙，碳酸锌或磷酸钙。
-
6.发明授权Medicament for preventive and therapeutic treatment of physical dysfunction caused by nerve damage 失效用于预防和治疗由神经损伤引起的身体功能障碍的药物公开(公告)号：US07968600B2
公开(公告)日：2011-06-28
申请号：US11670126
申请日：2007-02-01
IPC分类号： A01N37/10 , A01N31/04 , A01N37/18 , A01N37/12 , A01N37/44 , A61K31/19 , A61K31/07 , A61K31/16 , A61K31/195
CPC分类号： A61K31/19
摘要： A medicament for preventive and/or therapeutic treatment of a physical dysfunction such as motor dysfunction caused by nerve damage resulting from an accident, cerebral crisis and the like, which comprises as an active ingredient a compound or a salt thereof represented by the following general formula (I): wherein R1 to R5 represents hydrogen atom, an alkyl group, or an alkyl-substituted silyl group, X represents —CONH— or —NHCO—, and A represents a carboxylic acid-substituted aromatic group which may be substituted or a tropolonyl group which may be substituted.
摘要翻译： 一种用于预防和/或治疗身体功能障碍的药物，所述身体功能障碍例如由事故引起的神经损伤引起的运动功能障碍，脑部危象等，其包含作为活性成分的由以下通式表示的化合物或其盐 （I）表示：其中R1至R5表示氢原子，烷基或烷基取代的甲硅烷基，X表示-CONH-或-NHCO-，A表示可被取代的羧酸取代的芳基或 可以被取代的对基酮基。
-
7.发明申请MEDICAMENT FOR PREVENTIVE AND THERAPEUTIC TREATMENT OF PHYSICAL DYSFUNCTION CAUSED BY NERVE DAMAGE 失效预防和治疗由神经损伤引起的身体功能障碍的药物公开(公告)号：US20080182905A1
公开(公告)日：2008-07-31
申请号：US11670126
申请日：2007-02-01
IPC分类号： A61K31/19
CPC分类号： A61K31/19
摘要： A medicament for preventive and/or therapeutic treatment of a physical dysfunction such as motor dysfunction caused by nerve damage resulting from an accident, cerebral crisis and the like, which comprises as an active ingredient a compound or a salt thereof represented by the following general formula (I): wherein R1 to R5 represents hydrogen atom, an alkyl group, or an alkyl-substituted silyl group, X represents —CONH— or —NHCO—, and A represents a carboxylic acid-substituted aromatic group which may be substituted or a tropolonyl group which may be substituted.
摘要翻译： 一种用于预防和/或治疗身体功能障碍的药物，所述身体功能障碍例如由事故引起的神经损伤引起的运动功能障碍，脑部危象等，其包含作为活性成分的由以下通式表示的化合物或其盐 （I）：其中R 1至R 5表示氢原子，烷基或烷基取代的甲硅烷基，X表示-CONH-或-NHCO-， A表示可以被取代的羧酸取代的芳基或可以被取代的聚丙二醇基。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.025 秒)
